Status:
COMPLETED
Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections
Lead Sponsor:
General Hospital of Athens Elpis
Conditions:
Eye Diseases
Injection Complication
Eligibility:
All Genders
55+ years
Phase:
NA
Brief Summary
This study aims to evaluate the effect of topical prophylaxis with brinzolamide-brimonidine fixed combination on short-term intraocular pressure (IOP) elevation after intravitreal injections of anti-v...
Detailed Description
The intravitreal anti-VEGF (ranibizumab, bevacizumab, pegaptanib and aflibercept) are commonly used in the treatment of diabetic macular edema, neovascular age-related macular degeneration and other p...
Eligibility Criteria
Inclusion
- Patients scheduled for treatment with intravitreal injections of anti-vascular endothelial growth factors
Exclusion
- history of glaucoma or ocular hypertension
- use of topical medications (e.g. IOP-lowering medication, corticosteroids)
- pseudoexfoliation
- pigment dispersion syndrome
- corneal diseases
- active intraocular inflammation
- any intraocular surgery in the last 6 months
Key Trial Info
Start Date :
May 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2020
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04523844
Start Date
May 11 2020
End Date
July 30 2020
Last Update
August 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Elpis" General Hospital
Athens, Ambelokipi, Greece, 11522